Puma Biotechnology (NASDAQ:PBYI) Director Troy Edward Wilson Sells 5,000 Shares

Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Troy Wilson sold 5,000 shares of the stock in a transaction on Monday, September 14th. The stock was sold at an average price of $9.10, for a total value of $45,500.00. Following the sale, the director owned 54,750 shares in the company, valued at approximately $498,225. This represents a 8.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Puma Biotechnology Trading Up 1.5%

Shares of NASDAQ PBYI traded up $0.14 during mid-day trading on Wednesday, hitting $9.39. The company had a trading volume of 188,827 shares, compared to its average volume of 288,825. The company has a market capitalization of $484.71 million, a price-to-earnings ratio of 18.06 and a beta of 1.24. Puma Biotechnology, Inc. has a 1 year low of $4.30 and a 1 year high of $9.73. The stock’s 50-day moving average price is $8.71 and its 200-day moving average price is $7.65.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.15. Puma Biotechnology had a return on equity of 20.76% and a net margin of 11.50%.The business had revenue of $56.50 million for the quarter, compared to analysts’ expectations of $53.00 million. As a group, equities research analysts forecast that Puma Biotechnology, Inc. will post 0.37 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on PBYI shares. Wall Street Zen raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 15th. Weiss Ratings upgraded shares of Puma Biotechnology from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, August 21st. Finally, TD Cowen upped their price target on shares of Puma Biotechnology from $5.00 to $6.00 and gave the stock a “hold” rating in a report on Friday, August 7th. Two analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $6.00.

Institutional Investors Weigh In On Puma Biotechnology

Several hedge funds have recently bought and sold shares of PBYI. BlackRock Inc. bought a new position in shares of Puma Biotechnology in the 2nd quarter worth $30,856,000. Dimensional Fund Advisors LP raised its position in shares of Puma Biotechnology by 7.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,436,106 shares of the biopharmaceutical company’s stock valued at $9,175,000 after buying an additional 96,503 shares in the last quarter. Ritholtz Wealth Management lifted its holdings in shares of Puma Biotechnology by 11.6% during the 1st quarter. Ritholtz Wealth Management now owns 774,308 shares of the biopharmaceutical company’s stock worth $4,948,000 after acquiring an additional 80,307 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Puma Biotechnology during the 2nd quarter worth $5,214,000. Finally, Sei Investments Co. grew its position in Puma Biotechnology by 18.2% in the first quarter. Sei Investments Co. now owns 508,182 shares of the biopharmaceutical company’s stock worth $3,247,000 after acquiring an additional 78,257 shares in the last quarter. 61.29% of the stock is currently owned by institutional investors.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company focused on developing and commercializing medicines for the treatment of cancer. The company’s primary product is NERLYNX (neratinib), an oral tyrosine kinase inhibitor designed to target HER2 and other members of the human epidermal growth factor receptor family.

In the United States, NERLYNX is approved for the extended adjuvant treatment of adults with early-stage HER2-positive breast cancer following postoperative trastuzumab-based therapy.